Join
Live feed
·
PRReleasevia Quantisnow
Zai Lab Limited logo

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

ByQuantisnow·Wall Street's wire, on your screen.
ZLAB· Zai Lab Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZLAB (Zai Lab Limited) and more on Quantisnow.